drugset / Trial / NCT06937905
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
RandomizedParallel-groupOpen-labelTreatment
Summary
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Timeline
- Start
- 2026-02-06
- Primary completion
- 2029-02-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Tarlatamab | Protein / enzyme biologic | 10 mg | — |
| Subject | Topotecan | Small molecule | — | — |